Bayer advances research in the area of pulmonary hypertension
- Details
- Category: Bayer
Bayer HealthCare is working with the Ludwig Boltzmann Institute (LBI) for Lung Vascular Research in the research area of lung vascular diseases - especially pulmonary hypertension.
AstraZeneca and PTC Therapeutics announce strategic oncology drug discovery collaboration
- Details
- Category: AstraZeneca
AstraZeneca and PTC Therapeutics, Inc. (PTC) have entered into an exclusive research collaboration and license agreement for the application of PTC's proprietary GEMS™ technology (Gene Expression Modulation by Small-molecules) for the discovery and development of potential new therapies for cancer and other diseases for which there is a great unmet medical need.
Pfizer Files with the FDA for Review of Axitinib for Patients with Advanced Renal Cell Carcinoma
- Details
- Category: Pfizer
Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted Pfizer's filing for standard review of axitinib for patients with advanced renal cell carcinoma (RCC).
Bristol-Myers Squibb to Expand Access to Reyataz® in sub-Saharan Africa and India
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) announced a new agreement to expand access to Reyataz® (atazanavir sulfate). The immunity-from-suit agreement signed with Matrix Laboratories Limited, a Mylan Company, enables the generic company to manufacture and sell atazanavir, as well as stavudine and didanosine, in sub-Saharan Africa and India.
Investigational ultra-long-acting insulin degludec reduces hypoglycaemia and improves long-term control
- Details
- Category: Novo Nordisk
Ultra-long-acting insulin degludec, under development by Novo Nordisk, lowers blood glucose levels with significantly reduced rates of hypoglycaemia (low blood sugar) compared to insulin glargine, according to data presented at the 71st Scientific Sessions of the American Diabetes Association (ADA) in San Diego.
Bristol-Myers Squibb Foundation Awards $1.5 Million in Grants
- Details
- Category: Bristol-Myers Squibb
The Bristol-Myers Squibb Foundation awarded five grants totaling $1.5 million to organizations that will empower African American women with type 2 diabetes to better manage their disease while also leveraging their standing as leaders in their families and communities to influence the health of those around them.
Merck: Regulatory Update on Cladribine Tablets
- Details
- Category: Merck Group
Merck KGaA announced that following feedback from regulatory authorities the company has decided to no longer pursue the global approval process of Cladribine Tablets for the treatment of relapsing-remitting multiple sclerosis (MS).
More Pharma News ...
- Teachers and Schools Across North America Receive $10,000 Amgen Award for Science Teaching Excellence
- Boehringer Ingelheim and Ashoka announce a global partnership for "Making More Health"
- Abbott and Biotest Announce Global Agreement to Develop and Commercialize Novel Antibody for Autoimmune Diseases
- FDA panel endorses efficacy but not safety of Novartis drug ACZ885 for gouty arthritis
- Pivotal study showed vismodegib helped shrink tumours or heal lesions
- Genzyme Celebrates 20th Anniversary of Gaucher Disease Registry with Launch of New Web Platform
- Novartis begins construction of new state-of-the-art pharmaceutical manufacturing plant in St. Petersburg, Russia